कंपनी का अवलोकन
Arrowhead Pharmaceuticals, Inc. is a biotechnology enterprise focused on developing therapeutic medicines for the treatment of intractable diseases within the United States market. The company operates specifically within the healthcare sector, functioning under the broader industry classification of biotechnology, which implies a high-risk, high-reward environment driven by research and development cycles. As of the latest reported data, the firm holds a market capitalization of $9.27B, generating annual revenue of $1.09B, and employs a workforce of 711 individuals. These valuation and revenue figures indicate that the company has achieved a substantial scale in the biotechnology landscape, positioning it as a significant player capable of funding extensive clinical trials for its pipeline assets such as Plozasiran and Zodasiran.
वित्तीय स्वास्थ्य
Arrowhead Pharmaceuticals, Inc. reported a trailing twelve-month revenue of $1.09B and a net income of $202.26M, with an EBITDA standing at $325.65M. The substantial gap between the total revenue of $1.09B and the net income of $202.26M reveals a cost structure that retains significant profitability despite the heavy operational expenses typical of the biotechnology sector. The company generated free cash flow of $170.73M, which indicates robust financial flexibility to fund ongoing research and development without relying heavily on external capital markets. The firm demonstrates exceptional margin performance with a gross margin of 100.0%, an operating margin of 15.5%, and a profit margin of 18.5%, where the 100.0% gross margin suggests the elimination of the cost of goods sold relative to revenue, while the operating and profit margins reflect efficient management of overhead and total expenses. Regarding capital structure, the company holds cash reserves of $914.71M against total debt of $698.16M, resulting in a debt-to-equity ratio of 124.07, which characterizes a leveraged balance sheet typical for growth-stage biotechnology firms. The current ratio stands at 3.38, indicating a highly conservative position regarding short-term liquidity where current assets significantly exceed current liabilities. Furthermore, the return on equity is 75.5% and the return on assets is 14.4%, metrics that reveal highly effective management in generating returns on shareholder capital and utilizing the company's asset base to produce earnings.
मूल्यांकन आकलन
The trailing P/E ratio is recorded at 41.39, while the forward P/E ratio is negative at -15.41, implying that the market expects a significant shift in earnings trajectory or that future earnings are not yet projected to be positive based on current models. The price-to-book ratio is 16.01, which indicates a substantial market premium over the company's book value, suggesting that investors are willing to pay a high multiple for the firm's intangible assets and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 8.50 and an EV/EBITDA of 27.80 suggest that the market is pricing the company based on revenue generation and enterprise value relative to earnings before interest, taxes, depreciation, and amortization rather than traditional earnings multiples. The stock has exhibited high volatility with a 52-week high of $76.76 and a 52-week low of $9.63, meaning the current price sits significantly below the 52-week high and reflects a wide trading range typical of biotechnology stocks. The beta value is 1.27, which explains that the stock price is 27% more volatile than the broader market, indicating higher sensitivity to market movements compared to a benchmark index.
Growth & Income
The revenue growth year-over-year is an extraordinary 10461.3%, whereas earnings growth is marked as N/A, indicating that while top-line revenue is expanding rapidly, earnings data is not available for comparison in the current reporting period. As the earnings growth rate is not available for direct comparison with revenue, the implication is that the company is in a revenue-driven expansion phase where profitability metrics may fluctuate based on clinical trial outcomes and regulatory approvals. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all generated earnings back into growth initiatives, research, and clinical development rather than distributing cash to shareholders. The overall growth and income profile is characterized by explosive revenue expansion and a zero-dividend policy, typical for biotechnology companies prioritizing capital allocation toward their drug pipeline to achieve commercialization milestones.